Shalby Ltd
Shalby Q2 Results 2026 (FY27) investor presentation: Revenue & Margins
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
Guidance rank: #24 of 32 in Healthcare Services
See the sector's top 10 — free with your mobile number.
Based on Shalby Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Consolidated Total Revenue for Q2 FY27: ₹3,182 million vs ₹2,899 million in Q2 FY26, up 9.8% YoY (Pages 5, 6, 8, 9). Quarterly EBITDA: ₹464 mn in Q2 FY27 vs ₹461 mn in Q2 FY26; YoY growth: +0.8% (Page 8, 6).
From Shalby Ltd's Q2 FY27 earnings-call transcript · updated 3 Nov 2026.
How did Shalby's revenue grow in the September 2026 quarter?
- Consolidated Total Revenue for Q2 FY27: ₹3,182 million vs ₹2,899 million in Q2 FY26, up 9.8% YoY (Pages 5, 6, 8, 9)
- Standalone Total Revenue for Q2 FY27: ₹2,506 million vs ₹2,298 million in Q2 FY26, up 9.1% YoY (Pages 5, 14, 16)
- Segment-wise Q2 FY27 Revenue:
- Shalby Hospitals, Pharma & Franchise: ₹2,561.8 million (80.51%)
- Shalby International: ₹296.7 million (9.32%)
2 more points from Shalby Ltd's call on revenue
Create a free account to keep reading this call
What happened to Shalby's margins in Q2 FY27?
See what Shalby Ltd said on profitability & margins — free account, 30 seconds.
What capex is Shalby planning?
- Additional 40% total bed capacity available for organic growth with limited capex (Page 25).
- Mumbai hospitals under development within budget to provide access to important local markets (Page 25).
- Sustainable capex business model focusing on becoming preferred O&M partner on revenue sharing mode; aim to double ROCE in coming year due to operational leverage (Page 25).
- Implant business capacity enhancements at Shalby MedTech including:
2 more points from Shalby Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Shalby raising money or cutting debt?
See what Shalby Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Shalby's order book?
See what Shalby Ltd said on order book & pipeline — free account, 30 seconds.
Shalby Ltd — Quarterly revenue & net profit
Q2 FY27 figures are not in this chart yet. Latest shown: Jun 2026 (Q1 FY27). The Q2 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q1 FY27): revenue ₹331 Cr, net profit ₹10 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Shalby's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q4 FY25 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q3 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
Others in Healthcare Services this season
- Vijaya Diagnostic Centre (Q2 FY27)
Q2 FY27 Revenue from Operations: INR 2,554 Mn, up 26.7% YoY (Page 10, 9) . Key investor presentation takeaways from Vijaya Diagnostic Centre Ltd's Q2 FY27 inves
- Metropolis Healt (Q2 FY27)
Q2FY27 revenue from operations: INR 496.8 Cr, up 15.8% YoY (Page 11) . Key investor presentation takeaways from Metropolis Healthcare Ltd's Q2 FY27 investor pre
- Nephrocare Health Services (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹303.4 Cr, up 23.5% YoY from ₹245.7 Cr in Q2 FY26 (Page 9). Key investor presentation takeaways from Nephrocare Health Services
- Global Health Ltd (Q2 FY27)
Q2 FY2027 revenue from operations: INR 14,690 million, up 33.6% year-on-year (YoY). Key investor presentation takeaways from Global Health Ltd's Q2 FY27 investo
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- Aster DM Quality Care LtdGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Shalby Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Shalby Ltd Q2 FY27 results?
Consolidated Total Revenue for Q2 FY27: ₹3,182 million vs ₹2,899 million in Q2 FY26, up 9.8% YoY (Pages 5, 6, 8, 9). Quarterly EBITDA: ₹464 mn in Q2 FY27 vs ₹461 mn in Q2 FY26; YoY growth: +0.8% (Page 8, 6).
What is Shalby Ltd share price analysis?
Shalby Ltd currently shows a neutral. The stock trades at a P/E of 33.8 with a market cap of ₹1,329 Cr. Investors should review the full earnings analysis for detailed insights.
Is Shalby Ltd planning capital expenditure?
Additional 40% total bed capacity available for organic growth with limited capex (Page 25).
Keep Shalby Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.